Phase II study of chemoradiotherapy combined with gemcitabine and nab-paclitaxel for unresectable locally advanced pancreatic cancer
Phase 2
Recruiting
- Conditions
- nresectable locally advanced pancreatic cancer
- Registration Number
- JPRN-UMIN000028116
- Lead Sponsor
- agoya University Pancreatic Tumor Bord
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
1) Distant metastasis 2) Allergy to gemcitabine or nab-paclitaxel 3) Invasion to digestive tract 4) Severe allergy to drags 5) Infection 6) Severe cardiovascular disease 7) Severe basal disease 8) Double cancer 9) Peripheral sensory neuropathy or myelopathy 10) ascites or pleural effusion 11) Active digestive tract bleeding 12) Severe diarrhea 13) Fibroid lung 14) History of radiotherapy for abdomen 15) Uncontrolled cancer pain 16) Lung would be included within radiation field 17) Uncontrolled severe mental disease 18) Pregnant 19) Not obtained consent to this trail 20) Not appropriate for the study at the physician's assessment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method